Trump announces 100% chip tariff as Apple ups U.S. investment
Scott Hutton, the President and CEO of Biodesix Inc (NASDAQ:BDSX), recently reported a sale of company shares, according to a filing with the Securities and Exchange Commission. On February 11, Hutton sold 83,660 shares of Biodesix common stock. The shares were sold at an average price of $0.9242, generating a total of $77,318. This sale was conducted automatically to cover tax obligations upon the vesting of restricted stock units. The transaction comes as the stock has declined 9.5% over the past week, though InvestingPro analysis suggests the stock is currently undervalued.
In the same filing, it was noted that Hutton acquired 252,628 shares of common stock on February 10, following the vesting of restricted stock units. These transactions add to a series of recent stock movements by the executive, reflecting ongoing changes in his ownership stake in the company. Despite recent stock volatility, Biodesix maintains strong liquidity with a current ratio of 3.4 and impressive revenue growth of 48.9% in the last twelve months. InvestingPro subscribers can access additional insights, including 6 key ProTips and a comprehensive research report analyzing the company’s financial health, which is currently rated as FAIR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.